NCT05947695 Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer
| NCT ID | NCT05947695 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Good Samaritan Hospital Medical Center, New York |
| Condition | Solid Tumor, Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-03-02 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-03-02 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the randomized control trial is to estimate the effect of an oncology clinical nurse specialist-led early intervention multidisciplinary approach to palliative and survivorship care within two previously identified and validated patient groups having metastatic solid tumor malignancy on patient-reported symptom burden, patient-reported overall quality of life (QOL), distress, and overall survival. The primary hypothesis is that the effect of an oncology clinical nurse specialist- led early intervention multidisciplinary palliative and survivorship care model will be significantly higher, as compared to the standard of care approach to palliative and survivorship care, on the primary endpoint of patient-reported symptom burden for patients with metastatic solid tumor malignancy within favorable and very favorable risk groups. Symptom burden includes pain, tiredness, drowsiness, nausea, lack of appetite, depression, anxiety, shortness of breath, and wellbeing.
Eligibility Criteria
Inclusion Criteria: * adult patients (21 yrs and over) * metastatic solid tumor malignancy with very favorable and favorable prognostic curves * under the care of GSUH oncology and radiation oncology clinicians Exclusion Criteria: * patients with metastatic solid tumor malignancy who are \< 21 yrs of age * adult patients with metastatic solid tumor malignancy who are in standard risk and unfavorable prognostic curves * patients not under the care of GSUH oncology and radiation oncology clinicians
Contact & Investigator
Johnny Kao, MD
STUDY CHAIR
Good Samaritan University Hospital
Frequently Asked Questions
Who can join the NCT05947695 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Solid Tumor, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05947695 currently recruiting?
Yes, NCT05947695 is actively recruiting participants. Contact the research team at Johnny.Kao@chsli.org for enrollment information.
Where is the NCT05947695 trial being conducted?
This trial is being conducted at West Islip, United States.
Who is sponsoring the NCT05947695 clinical trial?
NCT05947695 is sponsored by Good Samaritan Hospital Medical Center, New York. The principal investigator is Johnny Kao, MD at Good Samaritan University Hospital. The trial plans to enroll 100 participants.